IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hellwig, S. M. M.
Right arrow Articles by van de Winkel, J. G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hellwig, S. M. M.
Right arrow Articles by van de Winkel, J. G. J.

 Previous Article  |  Next Article 

Infection and Immunity, August 2001, p. 4846-4850, Vol. 69, No. 8
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.8.4846-4850.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Immunoglobulin A-Mediated Protection against Bordetella pertussis Infection

Sandra M. M. Hellwig,1,2 Annemiek B. van Spriel,2,3 Joop F. P. Schellekens,4 Frits R. Mooi,1,5 and Jan G. J. van de Winkel2,6,*

Laboratory for Infectious Diseases Research,1 and Diagnostic Laboratory for Infectious Diseases and Perinatal Screening,4 National Institute of Public Health and the Environment, Bilthoven, and Immunotherapy Laboratory, Department of Immunology,2 Medarex Europe,3 Genmab,6 and Eijkman-Winkler Institute,5 University Medical Center, Utrecht, The Netherlands

Received 16 January 2001/Returned for modification 12 March 2001/Accepted 4 May 2001

Infection with Bordetella pertussis, the causative agent of pertussis (whooping cough) in humans, is followed by the production of antibodies of several isotypes, including immunoglobulin A (IgA). Little is known, however, about the role of IgA in immunity against pertussis. Therefore, we studied targeting of B. pertussis to the myeloid receptor for IgA, Fcalpha RI (CD89), using either IgA purified from immune sera of pertussis patients or bispecific antibodies directed against B. pertussis and Fcalpha RI (CD89 BsAb). Both IgA and CD89 BsAb facilitated Fcalpha RI-mediated binding, phagocytosis, and bacterial killing by human polymorphonuclear leukocytes (PMNL) and PMNL originating from human Fcalpha RI-transgenic mice. Importantly, Fcalpha RI targeting resulted in enhanced bacterial clearance in lungs of transgenic mice. These data support the capacity of IgA to induce anti-B. pertussis effector functions via the myeloid IgA receptor, Fcalpha RI. Increasing the amount of IgA antibodies induced by pertussis vaccines may result in higher vaccine efficacy.

* Corresponding author. Mailing address: Immunotherapy Laboratory, University Medical Center Utrecht, KC02.085.2, Lundlaan 6, 3584 EA Utrecht, The Netherlands. Phone: 31.30.2504306. Fax: 31.30.2504305. E-mail: J.vandewinkel{at}lab.azu.nl.

Infection and Immunity, August 2001, p. 4846-4850, Vol. 69, No. 8
0019-9567/01/$04.00+0   DOI: 10.1128/IAI.69.8.4846-4850.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2001 by the American Society for Microbiology. All rights reserved.